Benefits from long-term treatment in irritable bowel syndrome

Gastroenterology Research and Practice

Volumn , Issue , 2012, Pages

  Evangelista, Stefano ^a  

^a Menarini Ricerche SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ANTIDEPRESSANT AGENT; LAXATIVE; LINACLOTIDE; LOPERAMIDE; LUBIPROSTONE; MEBEVERINE; OTILONIUM BROMIDE; PLACEBO; PROKINETIC AGENT; SPASMOLYTIC AGENT;

ARTICLE; DRUG EFFICACY; HUMAN; IRRITABLE COLON; LONG TERM CARE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84856456740     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2012/936960     Document Type: Article

References (23)

1. Agréus L., Svrdsudd K., Talley N. J., Jones M. P., Tibblin G., Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study The American Journal of Gastroenterology 2001 96 10 2905 2914 (Pubitemid 32959532)
2. Halder S. L. S., Locke G. R. III, Schleck C. D., Zinsmeister A. R., Melton L. J. III, Talley N. J., Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study Gastroenterology 2007 133 3 799 807
3. Hahn B., Watson M., Yan S., Gunput D., Heuijerjans J., Irritable bowel syndrome symptom patterns: frequency, duration, and severity Digestive Diseases and Sciences 1998 43 12 2715 2718 (Pubitemid 29034926)
4. Hungin A. P. S., Whorwell P. J., Tack J., Mearin F., The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects Alimentary Pharmacology Therapeutics 2003 17 5 643 650 (Pubitemid 36418887)
5. Ford A. C., Forman D., Bailey A. G., Axon A. T. R., Moayyedi P., Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study Alimentary Pharmacology Therapeutics 2008 28 8 1013 1020
6. Ragnarsson G., Bodemar G., Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhoea, constipation and symptom variation during a prospective 6-week study European Journal of Gastroenterology and Hepatology 1998 10 5 415 421 (Pubitemid 28241429)
7. Spiller R. C., Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials The American Journal of Medicine 1999 107 5 91S 97S
8. Mller-Lissner S., Holtmann G., Rueegg P., Weidinger G., Lffler H., Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation Alimentary Pharmacology Therapeutics 2005 21 1 11 20 (Pubitemid 40175339)
9. Clavé P., Acalovschi M., Triantafillidis J. K., On behalf of the OBIS Study Investigators: randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distension and time to relapse in patients with irritable bowel syndrome Alimentary Pharmacology Therapeutics 2011 34 4 432 442
10. Villagrasa M., Boix J., Humbert P., Quer J. C., Aleatory clinical study comparing otilonium bromide with a fibre-rich diet in the treatment of irritable bowel syndrome Italian Journal of Gastroenterology 1991 23 8, supplement 1 67 70
11. Chey W. D., Chey W. Y., Heath A. T., Dukes G. E., Carter E. G., Northcutt A., Ameen V. Z., Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome The American Journal of Gastroenterology 2004 99 11 2195 2203 (Pubitemid 39524711)
12. Johnston J. M., Kurtz C. B., MacDougall J. E., Lavins B. J., Currie M. G., Fitch D. A., O'Dea C., Baird M., Lembo A. J., Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation Gastroenterology 2010 139 6 1877 1886
13. Carter N. J., Scott L. J., Lubiprostone: in constipation-predominant irritable bowel syndrome Drugs 2009 69 9 1229 1237
14. Chey W. D., Saad R. J., Panas R. M., Wable A., Ueno R., Discontinuation of lubiprostone treatment for irritable bowel syndrome with constipation is not associated with symptom increase or recurrence: results from a randomised withdrawal study Gastroenterology 2008 134 4, supplement 1 A401
15. Glende M., Morselli-Labate A. M., Battaglia G., Evangelista S., Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome European Journal of Gastroenterology and Hepatology 2002 14 12 1331 1338 (Pubitemid 36054922)
16. Kaptchuk T. J., Kelley J. M., Conboy L. A., Davis R. B., Kerr C. E., Jacobson E. E., Kirsch I., Schyner R. N., Bong H. N., Nguyen L. T., Park M., Rivers A. L., McManus C., Kokkotou E., Drossman D. A., Goldman P., Lembo A. J., Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome British Medical Journal 2008 336 7651 999 1003 (Pubitemid 351656091)
17. Ford A. C., Moayyedi P., Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome Alimentary Pharmacology Therapeutics 2010 32 2 144 158
18. Corazziari E., Bytzer P., Delvaux M., Holtmann G., Malagelada J. R., Morris J., Muller-Lissner S., Spiller R. C., Tack J., Whorwell P. J., Consensus report: clinical trial guidelines for pharmacological treatment of irritable bowel syndrome Alimentary Pharmacology Therapeutics 2003 18 6 569 580 (Pubitemid 37186606)
19. Jones R. H., Holtmann G., Rodrigo L., Ehsanullah R. S. B., Crompton P. M., Jacques L. A., Mills J. G., Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients Alimentary Pharmacology Therapeutics 1999 13 11 1419 1427 (Pubitemid 29516253)
20. Nyhlin H., Bang C., Elsborg L., A double-blind, placebo-controlled, randomised study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome Scandinavian Journal of Gastroenterology 2004 39 2 119 126 (Pubitemid 38253623)
21. Evangelista S., Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome Current Pharmaceutical Design 2004 10 28 3561 3568 (Pubitemid 39378335)
22. Mller-Lissner S., Kamm M. A., Musoglu A., Earnest D. L., Dunger-Baldauf C., Shetzline M. A., Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation The American Journal of Gastroenterology 2006 101 11 2558 2569 (Pubitemid 44665253)
23. Svedlund J., Sjdin I., Ottosson J., Dotevall G., Controlled study of psychotherapy in irritable bowel syndrome The Lancet 1983 2 8350 589 592 (Pubitemid 13051045)